Soleno Therapeutics, Inc. (SLNO) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
SLNO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SLNO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 98.6% | 7.9% | 11.0% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export SLNO earnings history in CSV or JSON format
Free sign-in required to download data
Soleno Therapeutics, Inc. (SLNO) Earnings Overview
As of May 8, 2026, Soleno Therapeutics, Inc. (SLNO) reported trailing twelve-month net income of $21M, reflecting +108.9% year-over-year growth. The company earned $0.38 per diluted share over the past four quarters, with a net profit margin of 11.0%.
Looking at the long-term picture, SLNO's historical earnings data spans multiple years. The company achieved its highest annual net income of $21M in fiscal 2025, representing a new all-time high.
Soleno Therapeutics, Inc. maintains positive profitability with a gross margin of 98.6%, operating margin of 7.9%, and net margin of 11.0%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), ACAD ($376M net income, 36.5% margin), RYTM (-$204M net income, -103.6% margin), SLNO has outperformed on profitability metrics. Compare SLNO vs RARE →
SLNO Earnings vs Peers
Earnings metrics vs comparable public companies
SLNO Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $21M | +111.9% | $15M | $0.39 | 11.0% | 7.9% |
| 2024 | -$176M | -351.0% | -$188M | $-4.38 | - | - |
| 2023 | -$39M | -62.0% | -$41M | $-2.36 | - | - |
| 2022 | -$24M | +22.1% | -$24M | $-2.87 | - | - |
| 2021 | -$31M | -25.5% | -$32M | $-5.81 | - | - |
| 2020 | -$25M | +19.9% | -$32M | $-3.68 | - | - |
| 2019 | -$31M | -130.8% | -$23M | $-15.78 | - | - |
| 2018 | -$13M | +14.9% | -$14M | $-9.54 | - | - |
| 2017 | -$16M | -29.9% | -$12M | $-26.18 | - | - |
| 2016 | -$12M | +24.2% | -$14M | $-58.35 | -831.6% | -938.1% |
See SLNO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLNO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLNO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSLNO — Frequently Asked Questions
Quick answers to the most common questions about buying SLNO stock.
Is SLNO growing earnings?
SLNO EPS is $0.38, with earnings growth accelerating to +108.9%. This exceeds the 5-year CAGR of N/A. TTM net income reached $21M.
What are SLNO's profit margins?
Soleno Therapeutics, Inc. net margin is +11.0%, with operating margin at +7.9%. Margins sit within typical range for the sector.
How consistent are SLNO's earnings?
SLNO earnings data spans 2012-2025. The accelerating earnings trend is +108.9% YoY. Historical data enables comparison across business cycles.